NTLA-2002 Interim Clinical Data Update

Bill, living with transthyretin amyloidosis, and his wife, Maura

Intellia THERAPEUTICS

November 14, 2022

Intellia Therapeutics' legal disclaimer

This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, efficacy and advancement of our clinical program for NTLA-2002 for the treatment of hereditary angioedema ("HAE"); its ability to generate data for NTLA-2002 as a potential single-dose treatment for HAE, including safety, kallikrein reduction and attack rate data including permanently preventing debilitating swelling attacks; its belief that NTLA-2002 may offer patients suffering from HAE a functional cure for their disease; its expectation to begin the Phase 2 dose-expansion of the study in the first half of 2023, and its expectation to expand country and site participation, including U.S. clinical sites, as part of the Phase 2 study; the advancement, expansion and acceleration of our CRISPR/Cas9 technology and *in vivo* pipeline to develop breakthrough genome editing treatments for people living with severe diseases; its ability to replicate or apply results achieved in preclinical or clinical studies, including those in our HAE program, in any future studies; statements regarding the timing of regulatory filings and clinical trial execution, including enrollment and dosing of patients, regarding our development programs; and potential commercial opportunities, including value and market, for our product candidates.

Any forward-looking statements in this presentation are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to our relationship with third parties, including our licensors and licensees; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates; risks related to the development and/or commercialization of any of Intellia's or its collaborators' product candidates, including that they may not be successfully developed and commercialized; risks related to the results of preclinical studies or clinical studies, including that they may not be positive or predictive of future results in connection with future studies; risks related to the successful enrollment of patients in the Phase 1/2 study for NTLA-2002 for the treatment of HAE; and the risk we will not be able to demonstrate our platform's modularity and replicate or apply results achieved in preclinical studies to develop additional product candidates, including to apply our proprietary CRISPR/Cas9 technology platform successfully to additional product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Intellia's most recent annual report on Form 10-K and quarterly report on Form 10-Q as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission ("SEC"). All information in this presentation is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Intellia THERAPEUTICS

Agenda

Welcome

Introduction

John Leonard, M.D.
Chief Executive Officer, Intellia Therapeutics

Review NTLA-2002 Interim Clinical Data

David Lebwohl, M.D.
Chief Medical Officer, Intellia Therapeutics

Closing Remarks and Q&A Session

Intellia THERAPEUTICS

Agenda

Welcome

Introduction

John Leonard, M.D.
Chief Executive Officer, Intellia Therapeutics

Review NTLA-2002 Interim Clinical Data

David Lebwohl, M.D.
Chief Medical Officer, Intellia Therapeutics

Closing Remarks and Q&A Session

Building a full-spectrum genome editing company

CRISPR-based Modular Platform

EMPLOY NOVEL EDITING AND DELIVERY TOOLS



In Vivo

CRISPR *is* the therapy

FIX THE TARGET GENE

Genetic diseases

Ex Vivo

CRISPR *creates* the therapy

REWIRE & REDIRECT CELLS

Immuno-oncology

Autoimmune diseases

Intellia THERAPEUTICS

Agenda

Welcome

Introduction

John Leonard, M.D.
Chief Executive Officer, Intellia Therapeutics

Review NTLA-2002 Interim Clinical Data

David Lebwohl, M.D.
Chief Medical Officer, Intellia Therapeutics

Closing Remarks and Q&A Session

Intellia THERAPEUTICS

In vivo CRISPR/Cas9 editing of *KLKB1* in patients with HAE

Interim data from ongoing Phase 1/2 study of NTLA-2002

Hereditary Angioedema (HAE) is a genetic disease associated with significant morbidity

WHAT IS HAE?

- Rare, autosomal dominant genetic disease
- Associated with frequent, severe and unpredictable attacks of painful swelling due to dysregulated bradykinin production

SYMPTOMS OF HAE

- Painful swelling attacks in extremities, face, stomach and GI tract
- Swelling of throat may cause difficulty swallowing or breathing, and in severe cases, can be fatal





~1 in 50,000

HAE patients worldwide[1]

Every 7-14 days

Average frequency of attacks for untreated patients[1]

Significant treatment burden exists[2]

Chronic dosing is required with current treatments

[1] Zuraw BL. Hereditary angioedema. *N Engl J Med*. 2008;359:1027-1036
[2] Radojicic, C., Riedl, MA., Craig, TJ, et al. Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. *Allergy Asthma Proc.* 2021; 42(3), S4–S10.

Targeting *KLKB1* gene expression for long-term prophylaxis of HAE attacks



1. Knocking out *KLKB1* gene is intended to prevent production of kallikrein
2. Decreasing kallikrein rebalances the pathway by reducing bradykinin production
3. Reducing bradykinin prevents HAE attacks

Kallikrein is a clinically validated therapeutic target for preventing HAE attacks

This presentation includes data for an investigational product not yet approved by regulatory authorities.

HAE, Hereditary Angioedema; **HMW**, High-molecular weight

Adapted from Zuraw BL. Hereditary angioedema. *N Engl J Med*. 2008;359:1027-1036

NTLA-2002 is a novel, investigational CRISPR/Cas9-based *in vivo* gene editing therapy



NTLA-2002 Uptake in Hepatocytes



This presentation includes data for an investigational product not yet approved by regulatory authorities.

LNP, Lipid Nanoparticle; **sgRNA**, Single Guide RNA

NTLA-2002 global Phase 1/2 study design: Two-part, multi-center study of NTLA-2002 in adults with HAE Types I and II

Today's interim data cover the Phase 1 part of the study
(Data cut-off: 28 September 2022)

Intervention:
Single dose administered via an intravenous (IV) infusion

PHASE 1
Open-label, single-ascending dose

- 75 mg (n=3)
- 50 mg (n=4)
- 25 mg (n=3)

PHASE 2
Expansion study to confirm recommended dose

Randomized

- Dose 1 (n=10)
- Dose 2 (n=10)
- Placebo Arm (n=5)

PRE-TREATMENT REGIMEN

Day -1: Oral dexamethasone 8 mg (or equivalent)

Day 1: IV dexamethasone 10 mg (or equivalent), IV or oral H1 and H2 blocker, C1-INH

PRIMARY OBJECTIVES

Evaluate safety & tolerability

OTHER OBJECTIVES

PK, PD, clinical efficacy (attacks)

PRIMARY OBJECTIVES

Clinical efficacy (attacks through week 16)

OTHER OBJECTIVES

PD, safety & tolerability, PK, QoL

50 mg cohort allowed up to 6 patients per protocol

C1-INH, C1 Esterase Inhibitor; **H1,** Histamine Receptor 1**; H2,** Histamine Receptor 2
PD, Pharmacodynamics; **PK,** Pharmacokinetics; **QoL**, Quality of Life

Key eligibility criteria (Phase 1)

INCLUSION

- ✓ Documented diagnosis of Type I or Type II HAE
- ✓ At least 3 investigator-confirmed HAE attacks within 90 days prior to screening
- ✓ Access to acute therapies to treat HAE attacks
- ✓ Concurrent therapy with standard-of-care, long-term prophylaxis allowed

EXCLUSION

- x Concomitant use of ecallantide or lanadelumab
- x Known hypersensitivity or prior infusion-related reaction to LNP components
- x History of cirrhosis, Hepatitis B, Hepatitis C or HIV

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Patient demographics & characteristics

Parameter	25 mg n = 3	50 mg n = 4	75 mg n = 3	All patients N = 10
Median Age, years (Min, Max)	30 (26, 52)	65 (52, 73)	45 (27, 49)	51 (26, 73)
Sex, n (%) Male Female	 3 (100%) –	 1 (25%) 3 (75%)	 2 (67%) 1 (33%)	 6 (60%) 4 (40%)
Median Weight, kg (Min, Max)	83 (78, 135)	86 (74, 107)	72 (64, 84)	83 (64, 135)
HAE Type, n (%) Type I Type II Unknown*	 2 (67%) 1 (33%) –	 1 (25%) 2 (50%) 1 (25%)	 2 (67%) 1 (33%) –	 5 (50%) 4 (40%) 1 (10%)

*Patient diagnosed based on C1-INH functional assay alone

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data Cut Off: 28 September 2022
HAE, Hereditary Angioedema

Patient reported HAE attack history

Parameter	25 mg n = 3	50 mg n = 4	75 mg n = 3	All patients N = 10
Prior Use of Long-Term Prophylaxis, n (%)				
Yes	2 (67%)	4 (100%)	3 (100%)	9 (90%)
No	1 (33%)	–	–	1 (10%)
Concomitant Long-Term Prophylaxis*, n (%)				
Yes	2 (67%)	3 (75%)	1 (33%)	6 (60%)
No	1 (33%)	1 (25%)	2 (67%)	4 (40%)
Historical Monthly Attack Rate, Mean (SD)	6.0 (6.92)	1.2 (0.47)	7.7 (8.00)	4.6 (5.83)
Typical Attack Severity, n (%)				
Mild	1 (33%)	2 (50%)	1 (33%)	4 (40%)
Moderate	1 (33%)	2 (50%)	1 (33%)	4 (40%)
Severe	1 (33%)	0	1 (33%)	2 (20%)

*Ongoing at time of study drug infusion

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data Cut Off: 28 September 2022

SD, Standard Deviation

NTLA-2002 was generally well-tolerated across all dose levels evaluated

- **Across all dose levels, the most frequent AEs were infusion-related reactions and fatigue**
  - All TEAEs were mild or moderate in severity (Grade 1 or 2 only)
  - All infusion-related reactions were considered mild (n = 5) or moderate (n = 2), resolving without clinical sequelae
  - All patients received a full dose of NTLA-2002
- **No clinically significant laboratory findings observed**
  - No increases in activated partial thromboplastin time
- **No treatment emergent SAEs or ≥ Grade 3 TEAEs were observed**

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data Cut Off: 28 September 2022
AE, adverse events; **SAE**, serious adverse event
TEAE, treatment-emergent adverse event

NTLA-2002 resulted in rapid and deep plasma kallikrein reduction at all dose levels



This presentation includes data for an investigational product not yet approved by regulatory authorities.

Dashed line represents targeted minimum reduction
SD, Standard Deviation

Clinically meaningful reductions in investigator-confirmed monthly attack rate observed through pre-specified 16-week follow-up period



		Attacks in Screening Period	Attacks in 16-Week Primary Observation Period	Mean (SD) % Change from Baseline Weeks 1-16	Mean (SD) % Change from Baseline Weeks 5-16
25 mg n = 3	Patient 1	1.1 / month	0.0 / month	**-91% (16%)**	**-89% (19%)**
	Patient 2	7.2 / month	2.0 / month		
	Patient 3	2.9 / month	0.0 / month		
75 mg n = 3	Patient 1	5.9 / month	3.5 / month	**-78% (32%)**	**-89% (19%)**
	Patient 2	4.0 / month	0.0 / month		
	Patient 3	4.3 / month	0.3 / month		

Analysis including 90-Day patient reported historical and screening period resulted in mean (SD) percent change of -94% (10%) and 90% (13%) in monthly attack rate for Week 1 to 16 in the 25 mg and 75 mg cohorts, respectively

SD, Standard Deviation

This presentation includes data for an investigational product not yet approved by regulatory authorities.

All patients have an ongoing attack-free interval with range of 2.3 to 10.6 months



This presentation includes data for an investigational product not yet approved by regulatory authorities.

Data Cut Off: 28 September 2022

A single dose of NTLA-2002 led to robust, dose-dependent and durable reductions in total plasma kallikrein levels

- Mean plasma kallikrein reductions between 65% and 92% were observed at nadir, with responses persisting for the duration of follow-up
- All patients in 25 mg and 75 mg cohorts have an ongoing attack-free interval of 2.3 to 10.6 months
  - First three patients treated have now been attack-free for 5.5 – 10.6 months
- Mean reductions in attacks from baseline of 89% at both 25 mg and 75 mg dose level (weeks 5-16)
- Patients who discontinued prophylactic therapy after NTLA-2002 infusion remained attack-free
- NTLA-2002 was generally well-tolerated; all AEs were of mild or moderate severity
- No further dose escalation is planned, Phase 2 expected to commence in first half of 2023

These data support the promise of CRISPR-based *in vivo* genome editing in humans

Agenda

Welcome

Introduction

John Leonard, M.D.
Chief Executive Officer, Intellia Therapeutics

Review NTLA-2002 Interim Clinical Data

David Lebwohl, M.D.
Chief Medical Officer, Intellia Therapeutics

Closing Remarks and Q&A Session

Q&A

NTLA-2002
Interim Clinical Data Update

Appendix

Majority of adverse events were mild in severity

Adverse events occurring in ≥ 2 patients	25 mg n = 3		50 mg n = 4		75 mg n = 3		All patients N = 10	
	Gr. 1	Gr. 2	Gr. 1	Gr. 2	Gr. 1	Gr. 2	Gr. 1	Gr. 2
Any TEAE (max grade)	2	1	2	1	1	2	5	4
Infusion-related reaction	2	–	1	1	2	1	5	2
Fatigue	1	–	2	1	2	–	5	1
COVID-19	2	–	1	–	1	–	4	–
Oropharyngeal pain	2	–	–	–	1	–	3	–
Headache	–	–	–	–	2	–	2	–
Upper respiratory tract infection	1	–	–	–	1	–	2	–
Viral upper respiratory tract infection	–	–	–	–	2	–	2	–

All other AEs (abdominal discomfort, abdominal pain, abdominal pain upper, arthralgia, asthenia, chest injury, depressed mood, diarrhea, disease prodromal stage, flank pain, insomnia, myalgia, rhinitis, sinusitis, soft tissue injury, somnolence, vomiting) were reported in one patient.

Patients counted once per row with highest grade reported.
Gr., Grade; **TEAE**, treatment-emergent adverse event

This presentation includes data for an investigational product not yet approved by regulatory authorities.

Intellia

THERAPEUTICS